DOVER, Del., Feb. 20th, 2018 (Businesswire) — Metatron (OTC:MRNJ), a mobile and web technology pioneer having released over 2000 apps on iTunes and Google Play with millions in sales and downloads, is pleased to report an update to Cannaboids™, a CBD sales, dispensary and news portal app which will allow cryptocurrency transactions for customer cannabis purchases.  The update is now available for Android and iOS devices.

According to a 2013 study in the British Journal of Clinical Pharmacology, cannibidol benefits including acting as an anti-inflammatory, antioxidant, and pain reliever.  One study by California Pacific Medical Center suggests CBD “turns off” the gene involved in the spread of breast cancer. These scientists found CBD inhibits ID-1, an action that prevents cancer cells from traveling lto distant tissues.

“We have received a number of request from users who want the flexibility of paying with cryptocurrency for their favorite CBD products, and since we are big believers in the benefits of CBD and the future of Crypto it made sense to add the payment option ” -Joe Riehl CEO Metatron.

Metatron has begun their capital raise to support the expansion and development of its cannabis and crypto apps by offering for a limited time its Series B preferred shares which are reverse split immune and we do accept Bitcoin and most major crypto currencies for qualified investors.

For more information email or visit and

Download our Apps:


Google Play:


Forward-Looking Statements: Any statements made in this press release which are not historical facts contain certain forward-looking statements, as such term is defined in the Private Litigation Reform Act of 1995, concerning potential developments affecting the business, prospects, financial condition and other aspects of the company to which this release pertains. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results of the specific items described in this release, and the company’s operations generally, to differ materially from what is projected in such forward-looking statements. Although such statements are based upon the best judgments of management of the company as of the date of this release, significant deviations in magnitude, timing and other factors may result from business risks and uncertainties including, without limitation, the company’s need for additional financing, which is not assured and which may result in dilution of shareholders, the company’s status as a small company with a limited operating history, dependence on third parties and the continuing popularity of the iOS operating system, general market and economic conditions, technical factors, receipt of revenues, and other factors, many of which are beyond the control of the company. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of such statements, and we disclaim any obligation to update information contained in any forward looking statement. Metatron retained Global Discovery Group Inc. for $30,500 for consulting services, CSC Partners for $1,500, Bas1 for $2501 and the company retained Pacific Equity Alliance LLC by issuing Integrative Business Alliance LLC 100m rule 144 for 1 year consulting services. Metatron does not grow, sell or distribute any substances that violate United States Law or the controlled substance act.